icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN
PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: THE ENDURANCE-5, 6 STUDY

 
 
  Reported by Jules Levin;
EASL 2018 April 13 Paris, Franceo
 
Tarik Asselah1, Tuan Nguyen2, Betty Yao3, Florence Wong4, Adam Mahomed5, Seng Gee Lim6, Samuel S Lee7, Armand Abergel8, Joe Sasadeusz9, Katia Alves3, Preethi Krishnan3, Zhenzhen Zhang3, Ariel Porcalla3, Roger Trinh3, Edward Gane10
 
1Centre de Recherche sur l'Inflammation, INSERM UMR 1149, UniversitÚ Paris Diderot, Department of Hepatology, AP-HP H˘pital Beaujon, Clichy, France; 2. Research and Education, Inc., San Diego, California, United States; 3. AbbVie Inc., North Chicago, Illinois, United States; 4. Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; 5. Faculty of Health Sciences, University of Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Department of Gastroenterology and Hepatology, South Africa; 6. Division of Gastroenterology and Hepatology, National University Health System, Singapore; 7. University of Calgary, Calgary, AB, Canada; 8. CHU Estaing, Clermont Ferrand, France; 9. Royal Melbourne Hospital, Melbourne, Australia; 10. Auckland Clinical Studies, Auckland, New Zealand

0413181

0413182

0413183

0413184

0413185

0413186

0413187

0413188